186 - Learn From the Experienced: Coffee and Cases in Resurging Vaccine-Preventable Diseases

Saturday, October 19, 2024

8:00 AM – 9:00 AM US PT

Location: 408 B

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1 hours of MOC Credit
CNE Credits: Maximum of 1 hours of ANCC Credit
ACPE Credits: ACPE 1 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Caitlin Li, MD MHQS (she/her/hers)

Assistant Professor of Pediatrics
Lurie Childrens Hospital
Chicago, IL, United States
Sarah Parker, MD

Professor of Pediatric Infectious Diseases
Pediatrics
University of Colorado/Children's Hospital Colorado
Aurora, CO, United States

Faculty(s)

KE

Kathryn Edwards, MD

Professor of Pediatrics Emerita
Vanderbilt University Medical Center
Nashville, TN, United States
Sheldon Kaplan, MD

Professor of Pediatrics
Baylor College of Medicine
Gary Marshall, MD

Professor of Pediatrics
Pediatrics
Norton Children's and University of Louisville School of Medicine
Louisville, KY, United States

Disclosure(s):

Caitlin Li, MD MHQS: No financial relationships to disclose

Sarah K. Parker, MD: Colorado Department of Health and Environment: Advisor/Consultant (Ongoing); Pfizer Global Bridges: Grant/Research Support (Ongoing)

Kathryn M. Edwards, MD: Bionet: Advisor/Consultant (Terminated); CSL Seqirus: Data Monitoring Committee (Ongoing); Dynavax: Advisor/Consultant (Ongoing); F. Hoffmann-La Roche Ltd.: Data Monitoring Committee (Ongoing); GlaxoSmithKline Biologicals: Advisor/Consultant (Ongoing); Merck and Company, Inc.: Data Monitoring Committee (Ongoing); Moderna, Inc.: Data Monitoring Committee (Ongoing); Novartis International AG: Data Monitoring Committee (Ongoing); Pfizer, Inc.: Data Monitoring Committee (Ongoing); Sanofi Pasteur LLC: Data Monitoring Committee (Ongoing); X-4 Pharma: Adjudication Committee (Ongoing)

Sheldon Kaplan, MD: Pfizer: Contract for study, Grant/Research Support

Gary S. Marshall, MD: GSK: Advisor/Consultant (), Grant/Research Support (), Honoraria (); Merck & Co., Inc.: Advisor/Consultant (), Grant/Research Support (), Honoraria (); Moderna: Advisor/Consultant (), Honoraria (); Pfizer: Advisor/Consultant (), Grant/Research Support (), Honoraria (); Sanofi: Advisor/Consultant (), Grant/Research Support (), Honoraria (); Seqirus: Advisor/Consultant (), Grant/Research Support (), Honoraria ()

Learning Objectives:

At the conclusion of this session, participants will be able to:

manage clinical scenarios related to vaccine preventable diseases;
recognize complications of vaccine preventable diseases;
humanize vaccine preventable diseases with a historical perspective.

Presentations:

8:00 AM – 8:20 AM US PT

Experienced Perspectives in VPD Part 1
Speaker: Kathryn M. Edwards, MD – Vanderbilt University Medical Center
8:20 AM – 8:40 AM US PT

Experienced Perspectives in VPD Part 2
Speaker: Sheldon Kaplan, MD – Baylor College of Medicine
8:40 AM – 9:00 AM US PT

Experienced Perspectives in VPD Part 3
Speaker: Gary S. Marshall, MD – Norton Children's and University of Louisville School of Medicine